Abstract
X-linked agammaglobulinemia (XLA), or Brutons disease, is the most common human primary humoral immunodeficiency. XLA is caused by mutations of the Brutons tyrosine kinase (BTK), a key regulator of B-cell physiology. Since the mid 80s, substitutive therapy by intravenous gammaglobulin infusions has significantly improved XLA patient survival and quality of life. Nevertheless, some frequent affections persist despite treatment, and lead to handicapping and further to morbid clinical complications for XLA individuals. Development of gene therapy by transfer of the BTK gene into hematopoietic progenitors could represent an alternative strategy for the treatment of Brutons disease, with the advantage of a definitive cure for XLA patients. Gene therapy of XLA could be considered as a paradigm for future expansion of gene therapy approaches for many other diseases, since future utilization may be strictly dependent on a marked improvement of risk-benefit ratio compared to pre-existing treatments.
Keywords: Bruton's disease, BTK, Immunodeficiency, B-cell, Retroviral vector, Hematopoietic stem cell
Current Gene Therapy
Title: Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Volume: 7 Issue: 4
Author(s): Thomas Moreau, Boris Calmels, Vincent Barlogis, Gerard Michel, Cecile Tonnelle and Christian Chabannon
Affiliation:
Keywords: Bruton's disease, BTK, Immunodeficiency, B-cell, Retroviral vector, Hematopoietic stem cell
Abstract: X-linked agammaglobulinemia (XLA), or Brutons disease, is the most common human primary humoral immunodeficiency. XLA is caused by mutations of the Brutons tyrosine kinase (BTK), a key regulator of B-cell physiology. Since the mid 80s, substitutive therapy by intravenous gammaglobulin infusions has significantly improved XLA patient survival and quality of life. Nevertheless, some frequent affections persist despite treatment, and lead to handicapping and further to morbid clinical complications for XLA individuals. Development of gene therapy by transfer of the BTK gene into hematopoietic progenitors could represent an alternative strategy for the treatment of Brutons disease, with the advantage of a definitive cure for XLA patients. Gene therapy of XLA could be considered as a paradigm for future expansion of gene therapy approaches for many other diseases, since future utilization may be strictly dependent on a marked improvement of risk-benefit ratio compared to pre-existing treatments.
Export Options
About this article
Cite this article as:
Thomas Moreau , Boris Calmels , Vincent Barlogis , Gerard Michel , Cecile Tonnelle and Christian Chabannon , Potential Application of Gene Therapy to X-Linked Agammaglobulinemia, Current Gene Therapy 2007; 7 (4) . https://dx.doi.org/10.2174/156652307781369128
DOI https://dx.doi.org/10.2174/156652307781369128 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
CNS & Neurological Disorders - Drug Targets Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design The Role of microRNAs in the Pathogenesis and Treatment of Hematopoietic Malignancies
Current Pharmaceutical Design Effect of Halofuginone on the Pathogenesis of Autoimmune Thyroid Disease in Different Mice Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Beta-Adrenergic Antagonists: Indications and Potential Immunomodulatory Side Effects in the Critically Ill
Current Medicinal Chemistry Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib
Current Pharmaceutical Design APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Reciprocity in Microbiome and Immune System Interactions and its Implications in Disease and Health
Inflammation & Allergy - Drug Targets (Discontinued) Non-Analgesic Effects of Opioids: Mechanisms and Potential Clinical Relevance of Opioid-Induced Immunodepression
Current Pharmaceutical Design Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Oral Tolerance and TGF-β -Producing Cells
Inflammation & Allergy - Drug Targets (Discontinued) Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Molecular and Cellular Glyco-Science – Part I)
Current Protein & Peptide Science FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Vitamin D and the Adaptive Immune System with Special Emphasis to Allergic Reactions and Allograft Rejection
Inflammation & Allergy - Drug Targets (Discontinued)